8-K

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)

8-K 2023-01-13 For: 2023-01-09
View Original
Added on April 05, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the SecuritiesExchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 9, 2023

NeuroOne Medical Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware 001-40439 27-0863354
(State or other jurisdiction<br><br> <br>of incorporation) (Commission File Number) (IRS Employer<br><br>Identification No.)

7599 Anagram Dr., Eden Prairie, MN 55344

(Address of principal executive offices and zip code)

952-426-1383

(Registrant’s telephone number including area code)

(Registrant’s former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 per share NMTC The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

NeuroOne Medical Technologies Corporation (the “Company”) appointed American Stock Transfer & Trust Company (“AST”) as its transfer agent and registrar effective January 9, 2023. All the Company’s registered shares of common stock have been transferred from Securities Transfer Corporation.

The contact information for AST is:

American Stock Transfer & Trust Company, LLC

6201 15^th^ Avenue

Brooklyn, NY 11219

Telephone: (800) 937-5449


1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOONE MEDICAL TECHNOLOGIES CORPORATION
Dated: January 13, 2023
By:

All values are in Euros.

2